(AOF) – OSE Immunotherapeutics announces the publication of positive phase 3 results of its vaccine in patients with lung cancer resistant to immunotherapy in the peer-reviewed journal “Annals of Oncology”. Tedopi improves overall survival with better tolerance and better quality of life as monotherapy versus chemotherapy, in HLA-A2 positive patients with advanced or metastatic NSCLC (non-small cell lung cancer) who have progressed after at least 12 weeks after sequential treatment with chemotherapy and IPC.
Nicolas Poirier, CEO of OSE Immunotherapeutics, comments: “Tedopi is the most advanced therapeutic cancer vaccine in clinical development. Our phase 3 data showing promising effects are now validated in a renowned international journal, ‘Annals of Oncology’, which represents a major breakthrough for everyone involved in the study.”
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
